Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Protease that specifically cleaves 'Lys-48'-linked polyubiquitin chains. Additionally we are shipping UCHL5 Proteins (15) and and many more products for this protein.
Showing 10 out of 109 products:
Human Polyclonal UCHL5 Primary Antibody for WB - ABIN1881974
Nishio, Kim, Kawai, Mizushima, Yamane, Hamazaki, Murata, Tanaka, Morimoto: Crystal structure of the de-ubiquitinating enzyme UCH37 (human UCH-L5) catalytic domain. in Biochemical and biophysical research communications 2009
Show all 5 Pubmed References
Human Monoclonal UCHL5 Primary Antibody for WB - ABIN1882285
Yao, Song, Xu, DeMartino, Florens, Swanson, Washburn, Conaway, Conaway, Cohen: Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. in Nature cell biology 2006
Show all 3 Pubmed References
Human Monoclonal UCHL5 Primary Antibody for WB - ABIN1882286
Lai, Chou, Chang, Liu, Lin: Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics. in Genome research 2000
Show all 3 Pubmed References
PI3K-dependent UCHL5 is required for high glucose-induced TGF-betaR1 (show CXCL11 Antibodies) protein expression in mesangial cells. UCHL5 is also required for high glucose-induced TGF-betaR1 (show CXCL11 Antibodies) protein deubiquitination, p21(WAF1 (show CDKN1A Antibodies)) and fibronectin (show FN1 Antibodies) protein expression and cell hypertrophy.
ubiquitinated loosely folded proteins, after becoming bound to the 26 S, interact with Ubp6/Usp14 or Uch37 to activate ATP hydrolysis and enhance their own destruction
this is the first report characterizing the physiological roles of Uch37 and Rpn13 in murine development and implicating a non-ATPase proteasomal protein, Rpn13, in the process of gametogenesis
Our studies provide a molecular mechanism by which UCHL5 mitigates TGFbeta (show TGFB1 Antibodies)-1 signaling by stabilizing Smad2 (show SMAD2 Antibodies)/Smad3 (show SMAD3 Antibodies). These data indicate that UCHL5 may contribute to the pathogenesis of idiopathic pulmonary fibrosis and may be a potential therapeutic target.
Positive cytoplasmic UCHL5 tumor immunoexpression is linked to increased survival of patients with small (<5 cm) tumors (p = 0.001), disease stages I-II (p = 0.025), and age 66 years or older (p = 0.037). UCHL5 is thus a potential marker in gastric cancer with new prognostic relevance.
our report demonstrates significant value in targeting USP14/UCHL5 with VLX1570 in drug-resistant Waldenstrom macroglobulinemia (WM) and carries a high potential for clinical translation
UCHL5 is a promising novel prognostic marker in lymph-node-positive rectal cancer. Our results also advance the currently limited knowledge of biomarkers in colorectal cancer treatment.
UCHL5 expression could function as a prognostic marker in pancreatic ductal adenocarcinoma, particularly at disease stages IIB to III. As UCHL5 is one of the few markers predicting increased survival, our results may be of clinical relevance.
this work implicates hRpn13 (show Adrm1 Antibodies) and Uch37 in cell cycle progression, providing a rationale for their function in cellular proliferation and for the apoptotic effect of the hRpn13 (show Adrm1 Antibodies)-targeting molecule RA190.
These results uncover a novel mechanism for E2F1 (show E2F1 Antibodies) transcriptional activation through removal of its Lys (show LYZ Antibodies)-63-linked ubiquitination by UCH37.
Uch37 consists of two domains, a globular UCH-domain and a fibrous C-terminal tail. The C-terminal residues of Uch37 are implicated in Rpn13 binding.
Data show that DEUBAD domain in RPN13 (ADRM1 (show Adrm1 Antibodies)) activates ubiquitin thioesterase L5 (UCH-L5), and the related DEUBAD domain in INO80G (NFRKB (show NFRKB Antibodies)) inhibits UCH-L5.
Data indicate that ubiquitin thioesterase L5 UCH37 (UCHL5) comprises a catalytic UCH domain followed by the four-helix (alpha8-alpha11) C-terminal domain.
Neither Uch37 alone nor the Uch37-Adrm1 (show Adrm1 Antibodies) or Uch37-Adrm1 (show Adrm1 Antibodies)-S1 complexes can hydrolyse di-ubiquitin efficiently; rather, incorporation into the 19S complex is required to enable processing of polyubiquitin (show UBB Antibodies) chains.
Protease that specifically cleaves 'Lys-48'-linked polyubiquitin chains. Deubiquitinating enzyme associated with the 19S regulatory subunit of the 26S proteasome. Putative regulatory component of the INO80 complex\; however is inactive in the INO80 complex and is activated by a transient interaction of the INO80 complex with the proteasome via ADRM1 (By similarity).
ubiquitin carboxyl-terminal hydrolase isozyme L5
, ubiquitin carboxyl-terminal hydrolase L5
, ubiquitin C-terminal hydrolase 37
, ubiquitin C-terminal hydrolase UCH37
, ubiquitin thioesterase L5
, INO80 complex subunit R
, ubiquitin carboxyl-terminal esterase L5